(Q51368060)

English

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety

scientific article published on 13 January 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

0 references

0 references

congestive heart failure

1 reference

based on heuristic

inferred from title

author name string

D Nathanson

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

B Ullman

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

U Löfström

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

A Hedman

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

M Frick

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

A Sjöholm

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

T Nyström

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

publication date

13 January 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

55

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

4

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

926-935

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Mechanical properties of primary cilia regulate the response to fluid flow

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Cardiac function in mice lacking the glucagon-like peptide-1 receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Cardiac metabolism as a target for the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

The adrenergic-fatty acid load in heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Diastolic Stiffness of the Failing Diabetic Heart

1 reference

https://api.crossref.org/works/10.1007%2FS00125-011-2440-X

21 January 2018

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sex and Type 2 Diabetes: Obesity‐Independent Effects on Left Ventricular Substrate Metabolism and Relaxation in Humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interactions of exendin-(9–39) with the effects of glucagon-like peptide-1-(7–36) amide and of exendin-4 on arterial blood pressure and heart rate in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/22246377

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-011-2440-X

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22246377

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51368060&oldid=2273929852"